Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis
- 678 Downloads
The association between nonsteroidal anti-inflammatory drugs (NSAIDs) and breast cancer survival is still controversial. The aim of our meta-analysis was to assess the survival benefit of NSAIDs.
A literature search was conducted in PubMed and EMBASE (to September 2014). A meta-analysis was performed with hazard ratios (HRs) and 95 % confidence intervals (CIs) as the effect measures. Subgroup analyses were based on time of NSAID use (before and after diagnosis), medication type (aspirin and other nonaspirin NSAIDs), and study design (cohort and case–control studies).
There were 16 eligible studies. Use of NSAIDs after diagnosis was significantly inversely associated with relapse/metastasis (HR 0.69, 95 % CI 0.59–0.80) and tended toward potentially protective effects on all-cause mortality, although significance was not reached (HR 0.79, 95 % CI 0.61–1.02). In cohort studies, the association between post-diagnostic use of NSAIDs and breast cancer survival was stronger with reduced heterogeneity (breast-cancer-specific mortality: HR 0.65, 95 % CI 0.48–0.89, I 2 = 65.3 %; all-cause mortality: HR 0.73, 95 % CI 0.57–0.92, I 2 = 83.2 %; relapse/metastasis: HR 0.73, 95 % CI 0.61–0.86, I 2 = 48.3 %). Aspirin use after diagnosis was significantly associated with breast-cancer-specific mortality (HR 0.69, 95 % CI 0.50–0.96) and relapse/metastasis (HR 0.75, 95 % CI 0.56–1.00), and tended toward a protective effect on all-cause mortality, although significance was not reached (HR 0.79, 95 % CI 0.60–1.03). Including cohort studies only, we obtained similar results and post-diagnostic use of aspirin was significantly associated with all-cause mortality (HR 0.72, 95 % CI 0.56–0.93).
NSAIDs and aspirin after but not before diagnosis were associated with improved breast cancer survival, including breast-cancer-specific mortality, all-cause mortality, and relapse/metastasis.
KeywordsNonsteroidal anti-inflammatory drugs Aspirin Breast cancer Cancer survival Meta-analysis
We thank the department of Surgical Oncology of First Hospital of China Medical University and the College of China Medical University for technical assistance. This work was supported by National Science Foundation of China (Nos. 81201888, 81372549, and 81172370), Specialized Research Fund for the Doctoral Program of Higher Education (No. 20122104110009), and Natural Science Foundation of Liaoning Province (No. 2014029201), Program of Education Department of Liaoning Province (L2014307).
Conflict of interest
All the authors declare that they have no conflict of interest.
- 17.Murray LJ, Cooper JA, Hughes CM, Powe DG, Cardwell CR (2014) Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case–control study in a breast cancer cohort from the UK Clinical Practice Research Datalink. Breast Cancer Res 16:R34CrossRefPubMedCentralPubMedGoogle Scholar
- 40.Chow LW, Yip AY, Chu WP, Loo WT, Toi M (2011) Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial. J Steroid Biochem Mol Biol 125:112–119CrossRefPubMedGoogle Scholar